Literature DB >> 29967227

Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.

Michael E Nassif1, Mikhail Kosiborod2,3.   

Abstract

Entities:  

Keywords:  diabetes mellitus, type 2; sodium-glucose transporter 2; treatment outcome

Mesh：

Substances：

Year:  2018        PMID： 29967227     DOI： 10.1161/CIRCULATIONAHA.117.022680

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  6 in total

1.  Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications.

Authors:  Felona Gunawan; Michael E Nassif; Caitlin Partridge; Tariq Ahmad; Mikhail Kosiborod; Silvio E Inzucchi
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-15

2.  Understanding constraints on integrated care for people with HIV and multimorbid cardiovascular conditions: an application of the Theoretical Domains Framework.

Authors:  Hayden B Bosworth; Daniel Gebhardt; Sarah E Gonzales; Jan E Hanson; Corrilynn O Hileman; Nwora Lance Okeke; Isabelle P Sico; Rajesh Vedanthan; Julie Schexnayder; Chris T Longenecker; Charles Muiruri; Allison R Webel
Journal:  Implement Sci Commun       Date:  2021-02-12

3.  Lessons Learned From a Patient-Centered, Team-Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program.

Authors:  Ian J Neeland; Sadeer G Al-Kindi; Nour Tashtish; Elke Eaton; Janice Friswold; Sara Rahmani; Khendi T White-Solaru; Imran Rashid; Diamond Berg; Mariam Rana; Claire Sullivan; Betul Hatipoglu; Peter Pronovost; Sanjay Rajagopalan
Journal:  J Am Heart Assoc       Date:  2022-07-29       Impact factor: 6.106

4.  Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry.

Authors:  Sanjay Divakaran; Avinainder Singh; David Biery; Junjie Yang; Ersilia M DeFilippis; Bradley L Collins; Mattheus Ramsis; Arman Qamar; Jon Hainer; Josh Klein; Christopher P Cannon; Donna M Polk; Jorge Plutzky; Khurram Nasir; James L Januzzi; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein
Journal:  Diabetes Care       Date:  2019-09-23       Impact factor: 17.152

Review 5.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

6.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Diabetes       Date:  2020-10-26       Impact factor: 9.461
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.